Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for non-alcoholic steatohepatitis with fibrosis
ISRCTN57849521Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jun 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing Losartan with Matched placebo (2 arms). Primary endpoint: Change in Kleiner fibrosis score. Started Jun 2011; status: completed.
02
Drugs
losartan
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on ISRCTN57849521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN57849521.